Neutralizing anti-SARS-CoV-2 antibodies and methods of use thereof
AssigneeThe Rockefeller University
InventorsMichel Nussenzweig, Davide F. Robbiani
Life of this patent
Estimating the term…
Abstract
This disclosure provides novel broadly neutralizing anti-SARS-CoV-2 antibodies or antigen-binding fragments thereof. The disclosed anti-SARS-CoV-2 antibodies constitute a novel therapeutic strategy in protection from SARS-CoV-2 infections.
Claims12
A recombinantly produced anti-SARS-CoV-2 antibody or antigen-binding fragment thereof that binds specifically to a SARS-CoV-2 antigen comprising a Spike (S) polypeptide of a human or an animal SARS-CoV-2, comprising a heavy chain variable region (HCVR) having the amino acid sequence of SEQ ID NO:
- 2900 and a light chain variable region (LCVR) having the amino acid sequence of SEQ ID NO:
- 2912.
A recombinantly produced anti-SARS-CoV-2 antibody or antigen-binding fragment thereof that binds specifically to a SARS-CoV-2 antigen comprising a Spike (S) polypeptide of a human or an animal SARS-CoV-2, comprising a heavy chain/light chain sequence pair of SEQ ID NOs:
- 2886/2898, 2886/2899, 2887/2898, 2887/2899, 2910/2921, 2910/2922, 2911/2921, or 2911/2922.
Dependencies are inferred from the claim text.